Supreme Court Upholds Mail-Order Access to Mifepristone

The US Supreme Court decided on Monday to restore full access to the abortion pill mifepristone after a lower court decision attempted to limit nationwide availability, according to NBC News.¹

“Mifepristone is a cornerstone of modern reproductive health. Studies have shown mifepristone to be safe and effective,” Natalie DiPietro Mager, PharmD, PhD, professor of pharmacy practice at Ohio Northern University and host of the Scripted for Her podcast, told Drug Topics. “It’s important that patients continue to have access to this medication, and telehealth is a key way for patients—especially those living in health professional shortage areas or without transportation—to be able to get the prescription products they need.”

The order, signed by Justice Samuel Alito, temporarily halts a ruling from the 5th US Circuit Court of Appeals that would have effectively banned the mailing of the medication and mandated in-person visits to receive it. This administrative stay is set to remain in effect until at least May 11, 2026, giving the High Court time to review emergency requests from drug manufacturers Danco Laboratories and GenBioPro.^1-3

These companies argued that the lower court’s restrictions would cause immediate confusion and regulatory chaos in a system where mifepristone is now used in approximately 63% of all US abortions.^3-5

READ MORE: Pharmacists Need Training and Legislative Support to Address Lack of Maternal Health Services

For the pharmacy profession, the Supreme Court’s intervention preserves a rapidly evolving landscape of reproductive care.⁴

“The Supreme Court’s decision puts the lower court’s decision on hold until at least May 11. That means there is no change to mifepristone access right now,” Mager. “However, it will be important for pharmacists to stay on top of the news and any developments as they unfold.”

Since the FDA permanently removed the Risk Evaluation and Mitigation Strategy (REMS) in-person dispensing requirement in early 2023, monthly pharmacy fills for the drug surged from a mean of 17.9 to over 2730 prescriptions.⁶

Mail-order pharmacies have become the dominant channel, accounting for nearly 98% of these fills in jurisdictions where telehealth is permitted. This shift has integrated pharmacists more deeply into medication abortion workflows, requiring them to manage REMS certification, contraindication screening, and complex shipment tracking.^5,6

The legal conflict stems from a challenge led by the state of Louisiana, which argues that mail-order access undermines state-level bans and causes medical emergencies.^1-3

However, Federal Judge David C. Joseph recently deferred to the FDA’s scientific expertise, allowing the medication to remain available while the agency completes a safety review commissioned by Health Secretary Robert F. Kennedy Jr., with an update due in approximately 6 months.^1,5

This judicial deference echoes a 2024 Supreme Court decision that found that previous challengers lacked legal standing, as they could not prove direct harm from the FDA’s regulatory expansions.³

Despite its 25-year clinical history, mifepristone remains under intense political fire. Senator Josh Hawley has introduced legislation to revoke the drug’s FDA approval for abortion while potentially allowing its use for Cushing syndrome—a nuance that would force pharmacists to manage the same molecule under 2 separate legal frameworks.^2,4-6

Sally Rafie, PharmD, BCPS, founder of the Birth Control Pharmacist, said to Drug Topics that pharmacists must stay vigilant, as these “active threats” could shut down care nationwide.⁴

Although the stay provides a reprieve from the “whiplash and chaos” described by providers like Planned Parenthood, Senate Minority Leader Chuck Schumer warns that the fight over mail-order access is just beginning. Organizations like the Massachusetts Abortion Access Project had already prepared to switch to misoprostol-only regimens before the stay, highlighting the volatile environment in which modern pharmacists must now operate.^1,2

“Should access to mifepristone be restricted, women will face difficulty in getting this FDA-approved medication. This will worsen health disparities and maternal health outcomes,” concluded Mager in her exclusive interview with Drug Topics. “Restrictions on mifepristone can also result in reduced access to miscarriage management as well as its use for other health-related reasons—such as Cushing’s syndrome or uterine fibroids.”

READ MORE: Women’s Health Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. Hurley L, Bendix A. Supreme Court temporarily restores full access to abortion pill. NBC News. May 4, 2026. Accessed May 4, 2026. https://www.nbcnews.com/politics/supreme-court/supreme-court-access-abortion-pill-mifepristone-rcna343445

2. Mack E. Supreme Court temporarily blocks appeals court ruling on abortion pill, restores wider access to drug. Fox News. May 4, 2026. Accessed May 4, 2026. https://www.foxnews.com/politics/supreme-court-temporarily-blocks-appeals-court-ruling-abortion-pill-restores-wider-access-drug

3. Howe A. Court issues temporary order allowing access to abortion pill by mail. SCOTUSblog. May 4, 2026. Accessed May 4, 2026. https://www.scotusblog.com/2026/05/abortion-pill-dispute-returns-to-supreme-court/

4. Nowosielski B, Rafie S. Pharmacists must commend and defend women’s reproductive health access. Drug Topics. April 21, 2026. Accessed May 4, 2026. https://www.drugtopics.com/view/pharmacists-must-commend-and-defend-women-s-reproductive-health-access

5. Nowosielski B. Federal judge temporarily upholds access to abortion medication. Drug Topics. April 9, 2026. Accessed May 4, 2026. https://www.drugtopics.com/view/federal-judge-temporarily-upholds-access-to-abortion-medication

6. Nowosielski B. Removal of REMS contributes to access of mifepristone. Drug Topics. April 16, 2026. Accessed May 4, 2026. https://www.drugtopics.com/view/removal-of-rems-contributes-to-access-of-mifepristone